# ACRO-POLIS study

# Symptoms and comorbidities at diagnosis of 472 acromegalic patients diagnosed between 2009 and 2014

Philippe Caron<sup>1</sup>, Thierry Brue<sup>2</sup>, Philippe Chanson<sup>3</sup>, Gérald Raverot<sup>4</sup>, Antoine Tabarin<sup>5</sup>, Anne Cailleux<sup>6</sup>, Brigitte Delemer<sup>7</sup>, Peggy Pierre Renoux<sup>8</sup>, Aude Houchard<sup>9</sup>, Frédérique Dupuis-Siméon<sup>9</sup>

¹Hôpital Larrey, Toulouse, ²Hôpital de la Timone, Marseille, ³CH Bicêtre, Le Kremlin Bicêtre, ⁴Hôpital Neuro-Cardiologique, Bron, ⁵Hôpital Haut-Lévêque, Pessac, ⁵CHU Rouen – Hôpital de Bois Guillaume, Bois Guillaume, <sup>7</sup>CHU Reims - Hôpital Robert Debré, Reims, ⁵CHU Bretonneau, Tours, ⁵IPSEN Pharma, Boulogne-Billancourt ; France

#### Introduction

 Acromegaly is characterized by chronic, excessive secretion of GH and increased IGF-1 levels caused by benign pituitary adenoma. It causes a broad range of signs and symptoms, which may occur over a long period of time and several years before acromegaly diagnosis.

#### Objective

 The ACRO-POLIS study aimed at describing the symptoms and comorbidities of acromegaly at diagnosis, in a large cohort of patients diagnosed between 2009 and 2014.

#### **Methods**

- Observational, cross-sectional, multicentre study conducted in France between September 2013 and June 2014.
- Adult patients with acromegaly diagnosed for less than 5 years were included.
- Data were collected retrospectively from patient medical files and confirmed by patient self-administered questionnaires.

#### Results

- In total, 648 patients were included in the study.
- The data from 472 patients, who met the selection criteria and had both CRF and patient questionnaire completed, were analyzed.


Characteristics	
	N=472
Mean (SD)	51.9 (14.3)
Mean (SD)	27.7 (5.3)
	n (%)
Male	202 (42.8%)
Female	270 (57.2%)
	Mean (SD) Mean (SD) Male

		N=	472
Time since diagnosis	of Acromegaly (months)		
	Mean (SD)	30.6	(17.8)
Acromegaly diagnos	ed by	n	(%)
	Endocrinologist	126	(29.5%)
	General practitioner*	69	(16.1%)
	Other**	232	(54.3%)

N: n	= <b>472</b> (%)
n	(%)
364	(78.8%)
84	(18.2%)
89	(19.7%)
362	(80.3%)
	,

<b>Table 4.</b> Biologica	al Characteristics at Di	agnosis
		N=472
GH (ng/mL)	Mean (SD)	18.7 (30.1)
IGF-1 (% ULN)	Mean (SD)	295 (160)
Serum prolactin (µg	g/L) for the GH + Prolactin	adenoma
	Mean (SD)	183 (650)

### **Results (continued)**



## Conclusions

• This study provides insights about symptoms and comorbidities of acromegalic patients recently diagnosed. Results confirm the broad range of comorbidities at diagnosis and the delayed diagnosis of acromegaly, and therefore highlight the efforts needed to improve the early detection of the disease.

Presented at the ECE 2015, 16–20 May 2015, Dublin, Ireland

This study was sponsored by Ipsen







Pituitary clinical